Systematic review of the safety of regular preventive asthma medications during pregnancy;Una revisión sistemática de la seguridad del uso de medicamentos preventivos para el asma durante el embarazo

Annals of Pharmacotherapy

Volumn 45, Issue 7-8, 2011, Pages 931-945

  Lim, Angelina ^a,b   Stewart, Kay ^a   König, Kai ^b   George, Johnson ^a  

^a MONASH UNIVERSITY   (Australia)

^b MERCY HOSPITAL FOR WOMEN   (Australia)

Author keywords

Asthma; Medication safety; Neonatology; Obstetrics; Pregnancy

Indexed keywords

ANTIASTHMATIC AGENT; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; CORTICOSTEROID; FLUTICASONE PROPIONATE PLUS SALMETEROL; LEUKOTRIENE RECEPTOR BLOCKING AGENT;

ARTICLE; ASTHMA; CINAHL; COCHRANE LIBRARY; CONGENITAL MALFORMATION; DATA EXTRACTION; DISEASE ASSOCIATION; DISEASE CONTROL; DRUG SAFETY; EMBASE; HUMAN; MEDICAL LITERATURE; MEDLINE; NONHUMAN; POSTMARKETING SURVEILLANCE; PREGNANCY; PRIORITY JOURNAL; RISK ASSESSMENT; SYSTEMATIC REVIEW;

ANTI-ASTHMATIC AGENTS; ASTHMA; FEMALE; HUMANS; PREGNANCY; PREGNANCY COMPLICATIONS; PRENATAL EXPOSURE DELAYED EFFECTS; TERATOGENS;

EID: 79960833729     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1P764     Document Type: Article

References (60)

1. Kwon H, Triche E, Belanger K, Bracken M. The epidemiology of asthma during pregnancy: prevalence, diagnosis, and symptoms. Immunol Allergy Clin North Am 2006;26:29-62.
2. American College of Obstetricians and Gynecologists and the American College of Allergy, Asthma and Immunology. Postition statement: the use of newer asthma and allergy medications during pregnancy. Ann Allergy Asthma Immunol 2000;84:475-480.
3. British Thoracic Society. Asthma in pregnancy. In: British guidelines on the management of asthma. Edinburgh, Scottish Intercollegiate Guideline Networks, 2009:71-72.
4. Global Initiative for Asthma. Special considerations-pregnancy. In: Global strategy for asthma management and prevention. Cape Town, South Africa, Medical Communication Resources Inc., 2008 update:70-1.
5. National Asthma Council of Australia. Pregnancy and asthma. In: Asthma management handbook. Melbourne, Australia: National Asthma Council Ltd., 2006:101-103.
6. National Heart, Lung and Blood Institute. Managing special situations-pregnancy. In: National Asthma Education and Prevention Program (NAEPP) Expert Panel Report 3. Guidelines for the Diagnosis and Management of Asthma. Rockville, MD: US Department of Health and Human Services, NIH Publication, 2007:38-39.
7. National Heart, Lung and Blood Institute. NAEPP expert panel report. Managing asthma during pregnancy: recommendations for pharmaco-logic treatment-2004 update. J Allergy Clin Immunol 2005;115:34-46.
8. Alexander S, Dodds L, Armson BA. Perinatal outcomes in women with asthma during pregnancy. Obstet Gynecol 1998;92:435-440.
9. Liu S, Wen SW, Demissie K, Marcoux S, Kramer MS. Maternal asthma and pregnancy outcomes: a retrospective cohort study. Am J Obstet Gy-necol 2001;184:90-96.
10. Blais L, Kettani FZ, Elftouh N, Forget A. Effect of maternal asthma on the risk of specific congenital malformations: a population-based cohort study. Birth Defects Res A Clin Mol Teratol 2010;88:216-222.
11. Bahna SL, Bjerkedal T. The course and outcome of pregnancy in women with bronchial asthma. Allergy 1972;27:397-406.
12. Enriquez R, Griffin MR, Carroll KN, et al. Effect of maternal asthma and asthma control on pregnancy and perinatal outcomes. J Allergy Clin Immunol 2007;120:625-630.
13. Sugai K, Ito M, Tateishi I, Funabiki T, Nishikawa M. Neonatal periven-tricular leukomalacia due to severe, poorly controlled asthma in the mother. Allergol Int 2006;55:207-212.
14. Martel MJ, Rey E, Beauchesne MF, et al. Control and severity of asthma during pregnancy are associated with asthma incidence in offspring: two-stage case-control study. Eur Respir J 2009;34:579-587.
15. Whincup P, Cook D, Papacosta O, Walker M. Birth weight and blood pressure: cross sectional and longitudinal relations in childhood. BMJ 1995;311:773-776.
16. Lao TT, Huengsburg M. Labour and delivery in mothers with asthma. Eur J Obstet Gynecol Reprod Biol 1990;35:183-190.
17. Stenius-Aarniala BS, Hedman J, Teramo KA. Acute asthma during pregnancy. Thorax 1996;51:411-414.
18. Chambers K. Asthma education and outcomes for women of childbear-ing age. Case Manager 2003;14:58-61.
19. Hale TW. Medications and mothers' milk-a manual of lactational pharmacology. Amarillo, TX: Hale Publishing, 2010.
20. Morgan MA, Cragan JD, Goldenberg RL, Rasmussen SA, Schulkin J. Obstetrician-gynaecologist knowledge of and access to information about the risks of medication use during pregnancy. J Matern Fetal Neonatal Med 2010;23:1143-1150.
21. Bakhireva LN, Schatz M, Chambers CD. Effect of maternal asthma and gestational asthma therapy on fetal growth. J Asthma 2007;44:71-76.
22. Gluck JC, Gluck PA. Asthma controller therapy during pregnancy. Am J Obstet Gynecol 2005;192:369-380.
23. Chambers C. Safety of asthma and allergy medications in pregnancy. Immunol Allergy Clin North Am 2006;26:13-28.
24. Källén B. The safety of asthma medications during pregnancy. Expert Opin Drug Saf 2007;6:15-26.
25. Morrow-Brown HM, Storey G. Beclomethasone dipropionate aerosol in the treatment of seasonal asthma and hay fever. Clin Exp Allergy 1974;4:331-341.
26. Greenberger PA, Patterson R. Beclomethasone diproprionate for severe asthma during pregnancy. Ann Intern Med 1983;98:478-480.
27. Dombrowski MP, Brown CL, Berry SM. Preliminary experience with triamcinolone acetonide during pregnancy. J Matern Fetal Med 1996; 5:310-313.
28. Wendel PJ, Ramin SM, Barnett-Hamm C, Rowe TF, Cunningham FG. Asthma treatment in pregnancy: a randomized controlled study. Am J Obstet Gynecol 1996;175:150-154.
29. Schatz M, Zeiger RS, Harden K, Hoffman CC, Chilingar L, Petitti D. The safety of asthma and allergy medications during pregnancy. J Allergy Clin Immunol 1997;100:301-306.
30. Dombrowski MP, Schatz M, Wise R, et al. Randomized trial of inhaled beclomethasone dipropionate versus theophylline for moderate asthma during pregnancy. Am J Obstet Gynecol 2004;190:737-744.
31. Kallen B, Rydhstroem H, Aberg A. Congenital malformations after the use of inhaled budesonide in early pregnancy. Obstet Gynecol 1999;93: 392-395.
32. Norjavaara E, de Verdier MG. Normal pregnancy outcomes in a population-based study including 2,968 pregnant women exposed to budes-onide. J Allergy Clin Immunol 2003;111:736-742.
33. Silverman M, Sheffer A, Diaz P V, et al. Outcome of pregnancy in a randomized controlled study of patients with asthma exposed to budesonide. Ann Allergy Asthma Immunol 2005;95:566-570.
34. Choi JS, Han JY, Kim MY, Velazquez-Armenta EY, Nava-Ocampo AA. Pregnancy outcomes in women using inhaled fluticasone during pregnancy: a case series. Allergol Immunopathol 2007;35:239-242.
35. Perrio MJ, Wilton LV, Shakir SAW. A modified prescription-event monitoring study to assess the introduction of Flixotide Evohaler into general practice in England: an example of pharmacovigilance planning and risk monitoring. Pharmacoepidemiol Drug Saf 2007;16:969-978.
36. Olesen C, Thrane N, Nielsen GL, Sørensen HT, Olsen J. A Population-based Prescription study of asthma drugs during pregnancy: changing the intensity of asthma therapy and perinatal outcomes. Respiration 2001; 68:256-261.
37. Bracken MB, Triche EW, Belanger K, Saftlas A, Beckett WS, Leaderer B P. Asthma symptoms, severity, and drug therapy: a prospective study of effects on 2205 pregnancies. Obstet Gynecol 2003;102:739-752.
38. Namazy J, Schatz M, Long L, et al. Use of inhaled steroids by pregnant asthmatic women does not reduce intrauterine growth. J Allergy Clin Immunol 2004;113:427-432.
39. Schatz M, Dombrowski MP, Wise R, et al. The relationship of asthma medication use to perinatal outcomes. J Allergy Clin Immunol 2004;113: 1040-1045.
40. Bakhireva L, Jones K, Schatz M, Johnson D, Chambers C. Asthma medication use in pregnancy and fetal growth. J Allergy Clin Immunol 2005; 116:503-509.
41. Martel M-J, Rey E, Beauchesne M-F, et al. Use of inhaled corticosteroids during pregnancy and risk of pregnancy induced hypertension: nested case-control study. BMJ 2005;330:230.
42. Clifton VL, Hodyl NA, Murphy VE, Giles WB, Baxter RC, Smith R. Effect of maternal asthma, inhaled glucocorticoids and cigarette use during pregnancy on the newborn insulin-like growth factor axis. Growth Horm IGF Res 2010;20:39-48.
43. Blais L, Beauchesne MF, Rey E, Malo JL, Forget A. Use of inhaled cor-ticosteroids during the first trimester of pregnancy and the risk of congenital malformations among women with asthma. Thorax 2007;62:320-328.
44. Blais L, Beauchesne MF, Lemiere C, Elftouh N. High doses of inhaled corticosteroids during the first trimester of pregnancy and congenital malformations. J Allergy Clin Immunol 2009;124:1229-1234.
45. Tata LJ, Lewis SA, McKeever TM, et al. Effect of maternal asthma, exacerbations and asthma medication use on congenital malformations in offspring: a UK population-based study. Thorax 2008;63:981-987.
46. Clifton VL, Rennie N, Murphy VE. Effect of inhaled glucocorticoid treatment on placental 11beta-hydroxysteroid dehydrogenase type 2 activity and neonatal birthweight in pregnancies complicated by asthma. Aust N Z J Obstet Gynaecol 2006;46:136-140.
47. Perrio M, Wilton L, Shakir SAW. A modified prescription-event monitoring study to assess the introduction of Seretide Evohaler in England: an example of studying risk monitoring in pharmacovigilance. Drug Saf 2007;30:681-695.
48. Wilton LV, Shakir SA. A post-marketing surveillance study of formoterol (Foradil): its use in general practice in England. Drug Saf 2002;25:213-223.
49. Mann RD, Kubota K, Pearce G, Wilton L. Salmeterol: a study by prescription-event monitoring in a UK cohort of 15,407 patients. J Clin Epidemiol 1996;49:247-250.
50. Wilton LV, Pearce GL, Martin RM, Mackay FJ, Mann RD. The outcomes of pregnancy in women exposed to newly marketed drugs in general practice in England. Br J Obstet Gynaecol 1998;105:882-889.
51. Jones KL, Johnson DL, D Van Maarseveen N, Chambers CD, Schatz M. Salmeterol use and pregnancy outcome: a prospective multi-center study. J Allergy Clin Immunol 2002;109:S156.
52. Merck Research Laboratories. Sixth annual report on exposure during pregnancy from the Merck Pregnancy registry for Singulair covering the period from February 20, 1998 through July, 2005. West Point, PA: Merck Research Labs, 2005.
53. Sarkar M, Koren G, Kalra S, et al. Montelukast use during pregnancy: a multicentre, prospective, comparative study of infant outcomes. Eur J Clin Pharmacol 2009;65:1259-1264.
54. Twaites BR, Wilton LV, Shakir SAW. Safety of zafirlukast: results of a postmarketing surveillance study on 7976 patients in England. Drug Saf 2007;30:419-429.
55. Bakhireva LN, Jones KL, Schatz M, et al. Safety of leukotriene receptor antagonists in pregnancy. J Allergy Clin Immunol 2007;119:618-625.
56. Falt A, Bengtsson T, Gyllenberg A, Lindberg B, Strandgarden K. Negligible exposure of infants to budesonide via breast milk. J Allergy Clin Immunol 2007;120:798-802.
57. Physicians' desk reference. 61st ed. Montvale, NJ: Thomson PDR, 2007.
58. Anderson DM, ed. Mosby's medical, nursing and allied health dictionary. 6th ed. St Louis, MO: Mosby Inc., 2002.
59. Schatz M, Leibman C. Inhaled corticosteroid use and outcomes in pregnancy. Ann Allergy Asthma Immunol 2005;95:234-238.
60. Briery C, Morrison J. High-risk pregnancy: risk factors. Gynaecology and obstetrics section. The Merck manual: online medical library. Updated January 2009. http://www.merckmanuals.com/professional/sec18/ ch262/ch262b.html (accessed 10 Sept 2010)